Victoria, BC, December 7, 2023--Aurinia Pharmaceuticals Inc. announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin, a second-generation oral calcineurin inhibitor for the treatment of lupus nephritis (LN).
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, November 6, 2023--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued its financial results for the three and nine months ended September 30, 2023. Amounts are expressed in U.S. dollars. The company reported net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter.
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, September 27, 2023--Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board.
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, August 28, 2023--Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company, bringing with them decades of combined leadership experience in the pharmaceutical and biotech industry.
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, August 25, 2023---Aurinia Pharmaceuticals Inc. issued its financial results for the three and six months ended June 30, 2023.Q2 Net revenue up 47% YoY to $41.5 million US. Aurinia had cash, cash equivalents and restricted cash and short-term investments of $350.7 million as of June 30, 2023.
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, July 24, 2023--Aurinia Pharmaceuticals Inc. announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal of the American College of Rheumatology.
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, May 10, 2023--Aurinia Pharmaceuticals Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V (including mixed classes III/V and IV/V) lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, May 8, 2023--Aurinia Pharmaceuticals Inc. issued its financial results for first quarter ended March 31, 2023. Total net revenue was $34.4 million for the quarter ended March 31, 2023, compared to $21.6 million in the prior year quarter ended March 31, 2022, representing significant growth of 59% year over year. T
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, April 26, 2023--Aurinia Pharmaceuticals Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly issued U.S. Patent (No. 11,622,991) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS.
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need
Victoria, BC, April 18, 2023--Aurinia Pharmaceuticals Inc. has announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the treatment of adults with active lupus nephritis (LN).
Aurinia Pharmaceuticals Inc.
Victoria (Biotech/Life Sciences) 20-49 Employees In BC (20-49 Employees Total)
Founded: 2013
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need